4.7 Article

Matrix metalloproteinase-1-mediated mesenchymal stem cell tumor tropism is dependent on crosstalk with stromal derived growth factor 1/C-X-C chemokine receptor 4 axis

期刊

FASEB JOURNAL
卷 28, 期 10, 页码 4359-4368

出版社

FEDERATION AMER SOC EXP BIOL
DOI: 10.1096/fj.14-252551

关键词

migration; MSCs; MMP-1; SDF-1; CXCR-4

资金

  1. Singapore Stem Cells Consortium [SSCC/08/143]

向作者/读者索取更多资源

Human bone marrow-derived mesenchymal stem cells (MSCs) have the unique ability to home toward injuries or tumor sites. We have previously shown that the tumor-tropic property is dependent on the intrinsic expression and activity of the matrix remodeling gene, matrix metalloproteinase 1 (MMP-1). Herein, crosstalk between MMP-1/protease activated receptor 1 (PAR-1) and the G-protein coupled receptor stromal-derived growth factor 1 (SDF-1)/C-X-C chemokine receptor 4 (CXCR-4) in facilitating cell migration was investigated. Gain-of-function and RNA interference (RNAi) technology were used to evaluate the interplay between the key players. The downstream effect on the tumor-tropic migration of MSCs was investigated using modified Boyden chamber assay. Neutralizing PAR-1 activation using monoclonal antibody and targeted knockdown of MMP-1 using RNAi resulted in decreased expression of SDF-1, which was not observed in control-RNAi-transfected cells. Overexpression of CXCR-4 failed to promote MSC migration; the percentage of migrated cells toward tumor cell conditioned medium was similar to the vector-transduced and the CXCR-4-transduced MSCs. Furthermore, inhibition of SDF-1/CXCR-4 signaling using AMD3100 reduced MSC migration through the deregulation of MMP-1 promoter activities, protein expression, and metalloproteinase activity. Collectively, our results showed that MMP-1-mediated MSC tumor tropism is dependent on crosstalk with the SDF-1/CXCR-4 axis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Medicine, Research & Experimental

Cytokinesis regulators as potential diagnostic and therapeutic biomarkers for human hepatocellular carcinoma

Yiting Qiao, Yunxin Pei, Miao Luo, Muthukumar Rajasekaran, Kam M. Hui, Jianxiang Chen

Summary: The article summarizes the importance of cytokinesis in maintaining cell ploidy level and its critical role in human hepatocellular carcinoma, including inducing abnormal cell ploidy and being potential therapeutic targets.

EXPERIMENTAL BIOLOGY AND MEDICINE (2021)

Article Pharmacology & Pharmacy

Diosgenin attenuates tumor growth and metastasis in transgenic prostate cancer mouse model by negatively regulating both NF-ΚB/STAT3 signaling cascades

Sakshi Sikka, Muthu K. Shanmugam, Kodappully Sivaraman Siveen, Tina H. Ong, Min Hee Yang, Jong Hyun Lee, Peramaiyan Rajendran, Arunachalam Chinnathambi, Sulaiman Ali Alharbi, Tahani Awad Alahmadi, Shireen Vali, Alan Prem Kumar, Gautam Sethi, Lingzhi Wang, Kam Man Hui, Kwang Seok Ahn

Summary: Research has shown that diosgenin can inhibit the activation of NF-Kappa B/STAT3 in prostate cancer cells and suppress tumor progression in in vivo models. This inhibition is achieved through the suppression of protein kinases and reporter gene activity, leading to reduced expression of tumorigenic gene products.

EUROPEAN JOURNAL OF PHARMACOLOGY (2021)

Article Biotechnology & Applied Microbiology

Centromere protein F promotes progression of hepatocellular carcinoma through ERK and cell cycle-associated pathways

Hongjin Chen, Fubing Wu, Haojun Xu, Guanqun Wei, Min Ding, Fanggui Xu, Amudha Deivasigamani, Guoren Zhou, Kam M. Hui, Hongping Xia

Summary: Hepatocellular carcinoma (HCC) is a deadly cancer type, with overexpression of centromere proteins (CENPs) playing a critical role in its progression. Specifically, overexpression of CENPF is associated with poor survival in HCC patients, promoting cell migration and EMT progression. Silencing CENPF inhibits cell growth both in vitro and in vivo, suggesting its potential as a biomarker for tackling HCC progression.

CANCER GENE THERAPY (2022)

Article Biochemistry & Molecular Biology

First use of gene therapy to treat growth hormone resistant dwarfism in a mouse model

Kian Chuan Sia, Shu Uin Gan, Siti Humairah Mohd Rodhi, Zhen Ying Fu, John J. Kopchick, Michael J. Waters, Kok Onn Lee

Summary: This study is the first to use gene therapy to treat GH-receptor deficiency. By injecting AAV-GHR, the serum GH levels decrease and the levels of GH-responsive IGF1, IGFBP3, and ALS increase in mice. It also causes a limited increase in body weight and length, similar to the response to rhIGF1 treatment in LS patients. This study is of great importance for the development of gene therapy for human LS treatment.

GENE THERAPY (2022)

Correction Multidisciplinary Sciences

PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein (vol 10, 2484, 2019)

Min Thura, Abdul Qader Al-Aidaroos, Abhishek Gupta, Cheng Ean Chee, Soo Chin Lee, Kam Man Hui, Jie Li, Yeoh Khay Guan, Wei Peng Yong, Jimmy So, Wee Joo Chng, Chin Hin Ng, Jianbiao Zhou, Ling Zhi Wang, John Shyi Peng Yuen, Henry Sun Sien Ho, Sim Mei Yi, Edmund Chiong, Su Pin Choo, Joanne Ngeow, Matthew Chau Hsien Ng, Clarinda Chua, Eugene Shen Ann Yeo, Iain Bee Huat Tan, Joel Xuan En Sng, Nicholas Yan Zhi Tan, Jean Paul Thiery, Boon Cher Goh, Qi Zeng

NATURE COMMUNICATIONS (2021)

Article Oncology

Tris(dibenzylideneacetone)dipalladium(0) (Tris DBA) Abrogates Tumor Progression in Hepatocellular Carcinoma and Multiple Myeloma Preclinical Models by Regulating the STAT3 Signaling Pathway

Loukik Arora, Chakrabhavi Dhananjaya Mohan, Min Hee Yang, Shobith Rangappa, Amudha Deivasigamani, Alan Prem Kumar, Ajaikumar B. Kunnumakkara, Manoj Garg, Arunachalam Chinnathambi, Sulaiman Ali Alharbi, Tahani Awad Alahmadi, Kanchugarakoppal S. Rangappa, Kam Man Hui, Gautam Sethi, Kwang Seok Ahn

Summary: STAT3 is a major oncogenic transcription factor that is constitutively activated in various human cancers, including HCC and MM. Tris DBA, a palladium-based compound, has shown inhibitory efficacy on STAT3 signaling in preclinical cancer models by elevating the expression of SHP2 and inhibiting cell proliferation, migration, invasion, and tumor metastasis. This study provides evidence for the potential consideration of Tris DBA in clinical trials for cancer treatment.

CANCERS (2021)

Article Cell Biology

Epigenetic derepression converts PPARγ into a druggable target in triple-negative and endocrine-resistant breast cancers

Ser Yue Loo, Nicholas L. Syn, Angele Pei-Fern Koh, Janet Cheng-Fei Teng, Amudha Deivasigamani, Tuan Zea Tan, Aye Aye Thike, Shireen Vali, Shweta Kapoor, Xiaoyuan Wang, Jiong Wei Wang, Puay Hoon Tan, George W. Yip, Gautam Sethi, Ruby Yun-Ju Huang, Kam Man Hui, Lingzhi Wang, Boon Cher Goh, Alan Prem Kumar

Summary: Clinical trials repurposing PPAR gamma agonists as anticancer agents have shown limited efficacy. Increased expression of PPARG is associated with better prognosis but negatively correlated with HDAC 1 and 2 expressions. Overexpression of HDAC blunts the anti-proliferative and anti-angiogenic responses to PPAR gamma agonists, which can be neutralized with HDAC inhibitors. Combined treatment with HDAC inhibitors is necessary to enhance the tumor-suppressive effects of PPAR gamma agonists in breast cancer cells, including triple-negative and endocrine-refractory subtypes. This combination therapy also inhibits angiogenesis and shows synergistic effects in ER alpha-positive cells.

CELL DEATH DISCOVERY (2021)

Article Biology

3-Formylchromone Counteracts STAT3 Signaling Pathway by Elevating SHP-2 Expression in Hepatocellular Carcinoma

Chakrabhavi Dhananjaya Mohan, Min Hee Yang, Shobith Rangappa, Arunachalam Chinnathambi, Sulaiman Ali Alharbi, Tahani Awad Alahmadi, Amudha Deivasigamani, Kam Man Hui, Gautam Sethi, Kanchugarakoppal S. Rangappa, Kwang Seok Ahn

Summary: This study demonstrates that 3-formylchromone inhibits the activated STAT3 signaling in hepatocellular carcinoma cells and effectively reduces tumor growth and metastasis in a mouse model. The researchers also found that 3-formylchromone does not cause substantial toxicity. Therefore, it has the potential to be a powerful agent for targeting STAT3 signaling in hepatocellular carcinoma.

BIOLOGY-BASEL (2022)

Article Multidisciplinary Sciences

The aberrant upregulation of exon 10-inclusive SREK1 through SRSF10 acts as an oncogenic driver in human hepatocellular carcinoma

Cunjie Chang, Muthukumar Rajasekaran, Yiting Qiao, Heng Dong, Yu Wang, Hongping Xia, Amudha Deivasigamani, Minjie Wu, Karthik Sekar, Hengjun Gao, Mengqing Sun, Yuqin Niu, Qian Li, Lin Tao, Zhen Yan, Menglan Wang, Shasha Chen, Shujuan Zhao, Dajing Chen, Lina Li, Fan Yang, Haojin Gao, Baodong Chen, Ling Su, Liang Xu, Ye Chen, Veerabrahma Pratap Seshachalam, Gongxing Chen, Jayantha Gunaratne, Wanjin Hong, Junping Shi, Gongying Chen, David S. Grierson, Benoit Chabot, Tian Xie, Kam Man Hui, Jianxiang Chen

Summary: In this study, the authors investigate the role of the splice variant of SREK1 and its upstream regulator SRSF10 in sustaining the oncogenic signal in hepatocarcinogenesis.

NATURE COMMUNICATIONS (2022)

Article Oncology

Procaine Abrogates the Epithelial-Mesenchymal Transition Process through Modulating c-Met Phosphorylation in Hepatocellular Carcinoma

Min Hee Yang, Chakrabhavi Dhananjaya Mohan, Amudha Deivasigamani, Arunachalam Chinnathambi, Sulaiman Ali Alharbi, Kanchugarakoppal S. Rangappa, Sang Hoon Jung, Hyejin Ko, Kam Man Hui, Gautam Sethi, Kwang Seok Ahn

Summary: Procaine inhibits the EMT process and c-Met-dependent signaling cascades, suggesting its potential as an anti-metastatic agent for HCC.

CANCERS (2022)

Article Biochemistry & Molecular Biology

Nimbolide enhances the antitumor effect of docetaxel via abrogation of the NF-Kappa B signaling pathway in prostate cancer preclinical models

Jingwen Zhang, Young Yun Jung, Chakrabhavi Dhananjaya Mohan, Amudha Deivasigamani, Arunachalam Chinnathambi, Sulaiman Ali Alharbi, Kanchugarakoppal S. Rangappa, Kam Man Hui, Gautam Sethi, Kwang Seok Ahn

Summary: This study investigates the combinational effect of docetaxel (DTX) and nimbolide (NL) on advanced prostate cancer. The results show that the co-administration of NL and DTX significantly reduces cell viability and enhances apoptosis in prostate cancer cells. NL also abolishes DTX-induced NF-kappa B activation and expression of antiapoptotic factors. The combination of NL and DTX demonstrates a synergistic antitumor effect and reduces metastases in prostate cancer models.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2022)

Review Oncology

Natural compounds targeting nuclear receptors for effective cancer therapy

Mangala Hegde, Sosmitha Girisa, Nikunj Naliyadhara, Aviral Kumar, Mohammed S. Alqahtani, Mohamed Abbas, Chakrabhavi Dhananjaya Mohan, Sudha Warrier, Kam Man Hui, Kanchugarakoppal S. Rangappa, Gautam Sethi, Ajaikumar B. Kunnumakkara

Summary: This review focuses on the therapeutic effects of natural compounds targeting nuclear receptors (NRs) in cancer treatment, highlighting their advantages and limitations. The study emphasizes the importance of NRs in gene expression regulation and the potential of natural compounds as oncology drugs.

CANCER AND METASTASIS REVIEWS (2023)

Article Oncology

Decanoic Acid Exerts Its Anti-Tumor Effects via Targeting c-Met Signaling Cascades in Hepatocellular Carcinoma Model

Min Hee Yang, Mina Lee, Amudha Deivasigamani, Duc Dat Le, Chakrabhavi Dhananjaya Mohan, Kam Man Hui, Gautam Sethi, Kwang Seok Ahn

Summary: Decanoic acid (DA) has been found to suppress the activation of c-Met and induce apoptosis in hepatocellular carcinoma cells, inhibiting tumor growth and progression. It has also shown anti-tumor effects in preclinical cancer models. Thus, DA has the potential to be a new therapeutic agent for hepatocellular carcinoma.

CANCERS (2023)

Article Gastroenterology & Hepatology

Differential expression of hepatic cancer stemness and hypoxia markers in residual cancer after locoregional therapies for hepatocellular carcinoma

Miran Kim, Kam Man Hui, Ming Shi, Nancy Reau, Costica Aloman

Summary: This study investigated the differential expression of hepatic cancer stem cells and hypoxia in residual HCC after TACE treatment. The findings suggest that these markers can predict non-response to TACE and that TACE-induced hypoxia may select for an aggressive HCC phenotype.

HEPATOLOGY COMMUNICATIONS (2022)

Article Medicine, Research & Experimental

STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway

Chengfei Zhang, Xiaoming Wang, Dan Fang, Ping Xu, Xiao Mo, Chao Hu, Alaa Abdelatty, Mei Wang, Haojun Xu, Qi Sun, Guoren Zhou, Junjun She, Jinglin Xia, Kam Man Hui, Hongping Xia

Summary: The study revealed that STK39 is highly overexpressed in clinical HCC tissues, induced by transcription factor SP1, and correlated with poor patient survival. Overexpression of STK39 promoted HCC cell proliferation, migration, and invasion, while depletion of STK39 attenuated growth and metastasis. Knockdown of STK39 induced HCC cell cycle arrest and apoptosis.

THERANOSTICS (2021)

暂无数据